AVTX — Avalo Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $16.48m
- $9.07m
- $1.92m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 6.75 | 6.7 | 5.4 | 18.1 | 1.92 |
Cost of Revenue | |||||
Gross Profit | 7.32 | 6.4 | 3.91 | 14.6 | 0.64 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 22.9 | 79.5 | 87.5 | 55.5 | 29.3 |
Operating Profit | -16.1 | -72.8 | -82.1 | -37.4 | -27.4 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -16 | -67.2 | -84.5 | -41.6 | -31.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -16.3 | -64.4 | -84.3 | -41.7 | -31.5 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -16.1 | -63.5 | -84.4 | -41.7 | -31.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -16.1 | -63.5 | -84.4 | -41.7 | -31.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1,092 | -1,676 | -2,430 | -1,062 | -104 |